Anti-inflammatory cytokine profile in acute coronary syndromes: Behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines

International Journal of Cardiology

Volumn 92, Issue 2-3, 2003, Pages 169-175

  Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Hatzinikolaou, Helen I ^a   Parissis, John T ^b   Papadopoulos, Elias D ^a   Trypsianis, Grigorios A ^a   Papadopoulou, Evropi ^a   Tentes, Ioannis K ^a   Karas, Spilios M ^b   Hatseras, Dimitrios I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

Acute coronary syndrome; Atherosclerosis; Interleukin 10; Metalloproteinase; Pro inflammatory cytokine

Indexed keywords

CHOLESTEROL; CYTOKINE; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 10744222775     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(03)00084-6     Document Type: Article

References (45)

1. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
2. Fuster V., Lewis A. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
4. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol. 68:(Suppl B):1991;28B-35B.
5. Fuster V., Badimon L., Badimon J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
6. Shah P.K. Pathophysiology of unstable angina. Cardiol Clin. 9:1991;11-26.
7. El Fawal M.A., Berg G.A., Wheatley D.J., et al. Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions. Br Heart J. 57:1987;329-335.
8. Maseri A. Inflammation, atherosclerosis and ischemic events - exploring the hidden side of the moon. N Engl J Med. 336:1997;1014-1016.
9. Mendall M.A., Patel P., Ballam L., et al. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 312:1996;1061-1065.
10. Ridker P.M., Cushman M., Stampfel M.J., et al. Plasma concentration of C reactive protein and risk of developing peripheral vascular disease. Circulation. 97:1998;425-428.
11. Davies M.J. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation. 97:1998;2382-2383.
12. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteinases are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 32:1998;368-372.
13. Fujimoto N., Mouri N., Iwata K., et al. A one-step sandwich enzyme immunoassay for human matrix metalloprotease 2(72-kDa gelatinse/type IV collagenase) using monoclonal antibodies. Clin Chim Acta. 221:1993;91-103.
14. Fujimoto N., Hosokawa N., Iwata K., et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloprotease 9 using monoclonal antibodies. Clin Chim Acta. 231:1994;79-88.
15. Kim S.H., Lee W.H., Kwon B.S., et al. Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. Jpn Circ J. 65:2001;136-138.
16. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 92:1995;1565-1569.
17. Kaartinen M., van der Wal A.C., van der Loos C.M., et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol. 32:1998;606-612.
18. Mallat Z., Corbaz A., Scoazec A., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 104:2001;1598-1603.
19. Moreau M., Brocheriou I., Petit L., et al. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation. 99:1999;420-426.
20. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 32:1998;368-372.
21. Brown D.L., Hibbs M.S., Kearney M., et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 91:1995;2125-2131.
22. Kokyx M., De Meyer G., Bortier H., et al. Luminal foam cell accumulation is associated with smooth muscle cell death in the intimal thickening of human saphenous vein grafts. Circulation. 94:1996;1255-1262.
23. Kokyx M., De Meyer G., Muhhring J., et al. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis. 120:1996;115-124.
24. Lacraz S., Nicod L.P., Chicheportiche R., et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 96:1995;2304-2310.
25. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 85:1999;17-24.
26. Wang P., Wu P., Siegel M.I., et al. Interleukin-10 inhibits nuclear factor-κB (NF-κB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem. 270:1995;9558-9563.
27. Lentsch A.B., Shanley T.P., Sarma V., et al. In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and Interleukin-13. J Clin Invest. 100:1997;2443-2448.
28. Mertz P.M., Dewitt D.L., Stetlerstevenson W.G., et al. Interleukin-10 suppression of monocyte prostaglandin-H synthase-2: mechanism of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem. 269:1994;21322-21329.
29. Arai T., Hiromatsu K., Nishimura H., et al. Endogenous interleukin-10 prevents apoptosis in macrophages during salmonella infection. Biochem Biophys Res Commun. 213:1995;600-607.
30. Cohen S.B., Crawley J.B., Mahan M.C., et al. Interleukin 10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 92:1997;1-5.
31. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 19:1999;2847-2853.
32. Shibata M., Endo S., Imada K., et al. Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. J Interferon Cytokine Res. 17:1997;145-150.
33. Sugita T., Watarida S., Katsuyama K., et al. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. J Thorac Cardiovasc Surg. 111:1996;545-553.
34. Yang Z., Zingarelli B., Szabo C. Crucial role of endogenous interleukin production in myocardial ischaemia/reperfusion injury. Circulation. 101:2000;1019-1026.
35. Koch W., Kastrati A., Bottiger C., Mehilli J., von Beckerath N., Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 159:2001;137-144.
36. Frangogiannis N.G., Smith W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 53:2002;31-47.
37. Smith D., Irving S., Sheldon J., Cole D., Kaski J.C. Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 104:2001;746-749.
38. Mazzone A., De Servi S., Vezzoli M., et al. Plasma levels of interleukin-2, -6, -10 and phenotypic characterization of circulating T-lymphocytes in ischemic heart disease. Atherosclerosis. 145:1999;369-374.
39. Kimur T., Kotajima N., Kanda T., Kuwabara A., Fukumura Y., Kobayashi I. Correlation of circulating interleukin-10 with thyroid hormone in acute myocardial infarction. Res Commun Mol Pathol Pharmacol. 110:2001;53-58.
40. Cervenak L., Morbidelli L., Donati D., et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood. 7:2000;2568-2573.
41. Silvestre J., Mallat Z., Duriez M., et al. Anti-angiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 6:2000;448-452.
42. Ikeda U., Ohkawa F., Seino Y., et al. Serum interleukin-6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol. 24:1992;579-584.
43. Taniguchi T., Koido Y., Aiboshi J., Yamashita T., Suzaki S., Kurokawa A. Change in ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 27:1999;1262-1264.
44. Tarkeltaub R.A. IL-10: an 'immunologic scalpel' for atherosclerosis? Arterioscler Thromb Vasc Biol. 19:1999;2823-2825.
45. Durrington P.N. Triglycerides are more important than epidemiology has suggested. Atherosclerosis. 141:(Suppl 1):1998;S57-S62.